Exclusive: Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO
The Wellcome Sanger Institute’s latest oncology spinout will enter the clinic in about 18 to 24 months with a new CEO at the helm and $28 million in Series A funds.
Called Mosaic Therapeutics, the startup is working on new targeted treatments from the labs of Sanger’s Mathew Garnett and Sanofi board member Emile Voest, who works at the Netherlands Cancer Institute and Oncode Institute. Also on the co-founding team is former Sanger head of technology translation Adrian Ibrahim.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.